WO2012170839A3 - Traitement d'une maladie neuro-inflammatoire par des inhibiteurs sélectifs de cox1 - Google Patents

Traitement d'une maladie neuro-inflammatoire par des inhibiteurs sélectifs de cox1 Download PDF

Info

Publication number
WO2012170839A3
WO2012170839A3 PCT/US2012/041586 US2012041586W WO2012170839A3 WO 2012170839 A3 WO2012170839 A3 WO 2012170839A3 US 2012041586 W US2012041586 W US 2012041586W WO 2012170839 A3 WO2012170839 A3 WO 2012170839A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
neuroinflammatory disease
selective cox1
cox1 inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/041586
Other languages
English (en)
Other versions
WO2012170839A2 (fr
Inventor
Karen J. Brunke
John CAUFIELD
Keni NII
Makoto OHMIYA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
CARDEUS PHARMACEUTICALS Inc
Original Assignee
Astellas Pharma Inc
CARDEUS PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, CARDEUS PHARMACEUTICALS Inc filed Critical Astellas Pharma Inc
Publication of WO2012170839A2 publication Critical patent/WO2012170839A2/fr
Publication of WO2012170839A3 publication Critical patent/WO2012170839A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des inhibiteurs hautement sélectifs de COX1 pouvant être utilisés pour traiter une maladie neuro-inflammatoire.
PCT/US2012/041586 2011-06-09 2012-06-08 Traitement d'une maladie neuro-inflammatoire par des inhibiteurs sélectifs de cox1 Ceased WO2012170839A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161495267P 2011-06-09 2011-06-09
US61/495,267 2011-06-09
US201161502657P 2011-06-29 2011-06-29
US61/502,657 2011-06-29

Publications (2)

Publication Number Publication Date
WO2012170839A2 WO2012170839A2 (fr) 2012-12-13
WO2012170839A3 true WO2012170839A3 (fr) 2013-02-21

Family

ID=47296765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/041586 Ceased WO2012170839A2 (fr) 2011-06-09 2012-06-08 Traitement d'une maladie neuro-inflammatoire par des inhibiteurs sélectifs de cox1

Country Status (1)

Country Link
WO (1) WO2012170839A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3148541B1 (fr) * 2014-05-28 2020-09-02 Universität Bern Thiazolidinones en tant qu'inhibiteurs de l'absorption d'anandamide cellulaire et leur utilisation dans le traitement de troubles psychiatriques ou neurologiques et de l'inflammation, en particulier d'une neuro-inflammation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191155A1 (en) * 2001-11-09 2003-10-09 Satoshi Aoki Triazole derivatives
US6803380B1 (en) * 1999-11-09 2004-10-12 Laboratoire Theramex 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
US20100022540A1 (en) * 2006-05-18 2010-01-28 Hans-Michael Eggenweiler Triazole derivatives ii
US20110034504A1 (en) * 2008-04-01 2011-02-10 Astellas Pharma Inc. Agent for preventing and/or treating vascular diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6803380B1 (en) * 1999-11-09 2004-10-12 Laboratoire Theramex 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
US20030191155A1 (en) * 2001-11-09 2003-10-09 Satoshi Aoki Triazole derivatives
US20100022540A1 (en) * 2006-05-18 2010-01-28 Hans-Michael Eggenweiler Triazole derivatives ii
US20110034504A1 (en) * 2008-04-01 2011-02-10 Astellas Pharma Inc. Agent for preventing and/or treating vascular diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JUNKO IMANISHE ET AL.: "Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor", BIOCHEMICAL PHARMACOLOGY, vol. 82, no. 7, 2 July 2011 (2011-07-02), pages 746 - 754 *

Also Published As

Publication number Publication date
WO2012170839A2 (fr) 2012-12-13

Similar Documents

Publication Publication Date Title
IL261768B (en) Devices and methods for tissue treatment
ZA201404077B (en) Neutralizing antibodies to hiv -1 and their use
EP3030323A4 (fr) Inhibiteurs de kdm1a pour le traitement d'une maladie
WO2012159051A3 (fr) Graphène chimiquement modifié
IL229474B (en) Cannabinoids for use in the treatment of neuropathic pain
EP2777895A4 (fr) Main de robot, et robot
AP3849A (en) Use of inhibitors of the activity or function of pi3k
EP2732937A4 (fr) Main de robot, et robot
WO2012145254A9 (fr) Procédés d'utilisation d'inhibiteurs de rorϒt pour traiter une maladie
BR112015002681A2 (pt) método para tratar um paciente e kit
BR112014009785A2 (pt) método para tratar ou reduzir efp
IL228719A0 (en) parp inhibitors for the treatment of cipn
IL230433A0 (en) Pain management methods
ZA201308459B (en) A topical formulation for treatment of hyperkeratotic skin
ZA201403739B (en) Methods of treatment with deferiprone
SI2846805T1 (sl) Zdravljenje zasvojenosti in motenj v obvladovanju impulzov z uporabo inhibitorjev PDE7
WO2012170839A3 (fr) Traitement d'une maladie neuro-inflammatoire par des inhibiteurs sélectifs de cox1
ZA201404738B (en) Treatment of type i and type ii diabetes
PT2846805T (pt) Macrociclos peptidomiméticos
EP2663746A1 (fr) Dispositif de traitement de gaz d'échappement
AU2011905428A0 (en) Treatment of Hydrocarbons
HK1194970A (en) Parp inhibitors for the treatment of cipn
AU2016201537A1 (en) Methods for chronic pain management and treatment using hcg
AU2012905402A0 (en) A method of treatment and agents useful for same
AU2012902036A0 (en) A method of treatment and agents useful for same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12796451

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014514887

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12796451

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: JP